Revenio Group
14.02 EUR
+4.32 %
14,352 following
REG1V
NASDAQ Helsinki
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Dividend
Investor consensus
+4.32 %
-1.13 %
-24.62 %
-37.41 %
-37.13 %
-49.57 %
-55.69 %
-77.92 %
+637.90 %
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
Read moreMarket cap
408.92M EUR
Turnover
2.16M EUR
P/E (adj.) (26e)
17.09
EV/EBIT (adj.) (26e)
19.2
P/B (26e)
1.91
EV/S (26e)
3.28
Dividend yield-% (26e)
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
6/8
2026
Interim report Q2'26
29/10
2026
Interim report Q3'26
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
New shares issued in Revenio’s directed share issue have been registered with the Finnish Trade Register
Revenio: Visionix acquisition completed slightly faster than expected
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
